Research & Development



  這一次如果不是被白登山下令要他們死守烽燧,他們說不定能干出一番讓所有人都吃驚的功業來。   如果來的匈奴像往常一樣只有一兩千人,我們自己就能一把火把匈奴全部燒死,這一次,來的敵人太多了,足足有兩萬之多,而且來的全是騎兵。久久国产av偷拍在线   一個面白無須的胖大男子輕聲問何愁有。开心色综合伊人   雲瑯收起魚竿,吊鉤上的羊肉已經不見了,剛才那條聰明的 魚吃掉了誘餌沒有上鉤。   “死道友不死貧道!”丁香五月婷婷开心综合   他們想在皇帝面前表現自己的勇武,他們想讓皇帝看見他們的勇猛,這一刻獲得的一分功勞,足足頂得上平日里的十分功勞。

Our discovery and development platforms for drug and cell-based therapies allow us to both create and retain significant value within our therapeutic franchise areas of cancer and inflammatory diseases. Scientists and physicians at Celgene are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.

Connect? Registries

The Connect??Registries are observational, hematologic patient registry studies in Multiple Myeloma (Connect?MM), Chronic Lymphocytic Leukemia (Connect?CLL) and Myelodysplastic Syndromes/Acute Myeloid Leukemia (Connect?MDS/AML) and are sponsored by Celgene Corporation. These studies are designed to observe the routine care of patients through the course of their disease. Unlike clinical trials, registries do not require or provide any specific medications or healthcare services, but leave those decisions to the treating doctors and their patients.
Connect? Registries logo